Plasma Exosome-Derived microRNAs as Potential Diagnostic and Prognostic Biomarkers in Brazilian Pancreatic Cancer Patients

Marin, Anelis Maria; Mattar, S. B.; Amatuzzi, Rafaela F.; Chammas, Roger; Uno, Miyuki; Zanette, Dalila Lucíola; Aoki, Mateus Nóbrega

doi:10.3390/biom12060769

Cited by 23 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specific miRNAs could be used as biomarkers for a high-sensible and non-invasive diagnosis of NSCLC at an early-stage [ 29 ]. miR-122-5p is highly expressed in various tumors, including renal cell carcinoma, ovarian cancer, liver cancer, and pancreatic cancer [ 30 – 33 ]. Thus, it could play a clinical role as a cancer marker in the future [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

The 5-year survival rate of non-small cell lung cancer (NSCLC) patients is very low. MicroRNAs (miRNAs) are involved in the occurrence of NSCLC. miR-122-5p interacts with wild-type p53 (wtp53), and wtp53 affects tumor growth by inhibiting the mevalonate (MVA) pathway. Therefore, this study aimed to evaluate the role of these factors in NSCLC. The role of miR-122-5p and p53 was established in samples from NSCLC patients, and human NSCLC cells A549 using the miR-122-5p inhibitor, miR-122-5p mimic, and si-p53. Our results showed that inhibiting miR-122-5p expression led to the activation of p53. This inhibited the progression of the MVA pathway in the NSCLC cells A549, hindered cell proliferation and migration, and promoted apoptosis. miR-122-5p was negatively correlated with p53 expression in p53 wild-type NSCLC patients. The expression of key genes in the MVA pathway in tumors of p53 wild-type NSCLC patients was not always higher than the corresponding normal tissues. The malignancy of NSCLC was positively correlated with the high expression of the key genes in the MVA pathway. Therefore, miR-122-5p regulated NSCLC by targeting p53, providing potential molecular targets for developing targeted drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Speci c miRNAs could be used as biomarkers for a high-sensible and non-invasive diagnosis of NSCLC at an early-stage 28 . miR-122-5p is highly expressed in various tumors, including renal cell carcinoma, ovarian cancer, liver cancer, and pancreatic cancer 11,26,32,37 ; thus, it might play a clinical role as a cancer marker in the future 13,53 . p53 protein has a research history of nearly 50 years, and it is the gene with the highest correlation with human tumors found so far 15 .…”

Section: Discussionmentioning

confidence: 99%

MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer

Wu¹,

Zheng²,

Zhou³

et al. 2022

Preprint

View full text Add to dashboard Cite

The 5-year survival rate of non-small cell lung cancer (NSCLC) patients is extremely low. microRNAs (miRNAs) are involved in the occurrence of NSCLC. miR-122-5p interacts with wild-type p53 (wtp53), and wtp53 affects tumor growth by inhibiting the mevalonate (MVA) pathway. Therefore, the aim of this study was to evaluate the role of these factors in NSCLC. The role of miR-122-5p and p53 was established in samples from NSCLC patients, as well as in human NSCLC cells A549 using the miR-122-5p inhibitor, miR-122-5p mimic, and si-p53. Our results showed that the inhibition of miR-122-5p expression led to the activation of p53, which in turn inhibited the progression of the MVA pathway in the NSCLC cells A549, hindered cell proliferation and migration as well as promoted apoptosis. miR-122-5p was negatively correlated with p53 expression in p53 wild-type NSCLC patients. The expression of key genes in the MVA pathway in tumors of p53 wild-type NSCLC patients was not always higher than that of their corresponding normal tissues. The malignancy of NSCLC was positively correlated with the high expression of the key genes in the MVA pathway. Therefore, miR-122-5p regulated NSCLC by targeting p53, providing potential molecular targets for the development of targeted drugs.

show abstract

“…Several studies have reported on the utility of circulating miRNAs as potential biomarkers in PDAC [ 135 , 147 , 152 , 153 , 154 , 155 ]. One study found that themiR-155-5p was not only upregulated in both tumor tissues and plasma of patients with PDAC, but levels of this miRNA were also associated with tumor stage and poor prognosis [ 156 , 157 , 158 ].…”

Section: Micrornasmentioning

confidence: 99%

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer

Raufi

May

Hadfield

et al. 2023

IJMS

View full text Add to dashboard Cite

Pancreatic cancer is a highly aggressive malignancy with a climbing incidence. The majority of cases are detected late, with incurable locally advanced or metastatic disease. Even in individuals who undergo resection, recurrence is unfortunately very common. There is no universally accepted screening modality for the general population and diagnosis, evaluation of treatment response, and detection of recurrence relies primarily on the use of imaging. Identification of minimally invasive techniques to help diagnose, prognosticate, predict response or resistance to therapy, and detect recurrence are desperately needed. Liquid biopsies represent an emerging group of technologies which allow for non-invasive serial sampling of tumor material. Although not yet approved for routine use in pancreatic cancer, the increasing sensitivity and specificity of contemporary liquid biopsy platforms will likely change clinical practice in the near future. In this review, we discuss the recent technological advances in liquid biopsy, focusing on circulating tumor DNA, exosomes, microRNAs, and circulating tumor cells.

show abstract

Plasma Exosome-Derived microRNAs as Potential Diagnostic and Prognostic Biomarkers in Brazilian Pancreatic Cancer Patients

Cited by 23 publications

References 55 publications

MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer

MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer

MiR-122-5p regulates the mevalonate pathway by targeting p53 in non-small cell lung cancer

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer

Contact Info

Product

Resources

About